Quick Answer
Korro Bio, Inc. reported Cash and Equivalents of $21.82 million for fiscal year 2025.
Korro Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $21.82M | -60.8% |
| 2024 | $55.64M | -66.5% |
| 2023 | $166.15M | +354.0% |
| 2023 | $36.60M | +0.7% |
| 2022 | $36.33M | -54.4% |
| 2021 | $79.64M | -63.9% |
| 2020 | $220.34M | +10.1% |
| 2019 | $200.16M | +374.4% |
| 2018 | $42.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.16M | -61.8% | -28.1% |
| June 30, 2025 | $33.61M | -63.1% | -47.6% |
| March 31, 2025 | $64.14M | -53.8% | +15.3% |
| December 31, 2024 | $55.64M | -66.5% | -12.0% |
| September 30, 2024 | $63.21M | +51.5% | -30.7% |
| June 30, 2024 | $91.15M | +129.5% | -34.3% |
| March 31, 2024 | $138.80M | +239.8% | -16.5% |
| December 31, 2023 | $166.15M | +219.8% | +298.2% |
- Korro Bio, Inc. showed a decrease of -60.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Korro Bio, Inc.’s cash and equivalents has declined by 48.3% (from $42.19 million to $21.82 million).
- The most recent figure is from Korro Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: